Terminated based on interim efficacy data that did not meet the Sponsor's criteria.

This is a multi-center, randomized, double-masked, proof-of-concept study in patients with Active Noninfectious Intermediate, Posterior, or Panuveitis.

This study will consist of a 2-week screening period (+7 days), 24-week treatment period, followed by a 24-week extension period, and a 4-week follow up period for a total of up to 55 weeks. Each participant will be randomized to receive one of two doses of ESK-001 daily for 24 weeks. Participants that do not meet the treatment failure criteria at Week 24 will continue into the extension period.

Key Inclusion Criteria:

• Able and willing to provide consent

• Male and females, age 18 to 70 years

• Diagnosis of active noninfectious intermediate, posterior or panuveitis

• Must have active uveitis at Screening in at least one eye as defined by:

  1. Active inflammatory chorioretinal and/or inflammatory retinal vascular lesion or lesions, or
  2. ≥ 2+ VH in accordance with the NEI/SUN criteria

• Males and females must use highly effective methods of contraception for the entirety of the study

Key Exclusion Criteria:

• Diagnosis of infectious uveitis
• Has elevated intraocular pressures or severe glaucoma
• Positive for HIV, Hepatitis B or C or active or inadequately latent tuberculosis at screening
• Positive for syphilis at screening
• Patients with QTcF >450 msec (both males and females) at screening
• Known active malignancy or history of malignancy within the past 5 years
• History of chronic drug or alcohol abuse
• Live vaccines
• No planned ocular or any other surgery during the course of the study

Other protocol-defined inclusion/exclusion criteria apply.